Heron Therapeutics (HRTX) Q3 2024 earnings summary

Executive summary

• Q3 2024 net product sales reached $32.8M, up from $31.4M in Q3 2023, with nine-month sales at $103.5M, reflecting strong revenue growth and improved operational efficiency.

• Net loss for Q3 2024 narrowed to $4.8M ($0.03/share), a significant improvement from $25.0M ($0.17/share) in Q3 2023, driven by cost reductions and improved margins.

• FDA approved ZYNRELEF Vial Access Needle (VAN) in September 2024, with launch set for Q4; ZYNRELEF included in CMS NOPAIN Act final rule, ensuring favorable reimbursement through at least 2027.

• CrossLink partnership is expanding ZYNRELEF's reach, driving early growth and commercial expansion.

• Full-year 2024 guidance narrowed for product revenues, adjusted operating expenses, and adjusted EBITDA, with YTD 2024 cash burn under $10M.

Financial highlights

• Gross profit for Q3 2024 was $23.4M (71% margin), up from $13.2M (42%) in Q3 2023; nine-month gross profit doubled to $75.1M.

• Q3 2024 net loss was $4.8M, a significant improvement from $25.0M in Q3 2023.

• Cash and short-term investments at quarter-end were $70.9M, expected to cover at least 12 months of operations.

• Operating expenses for Q3 2024 were $27.8M, down from $38.2M in Q3 2023.

• Net cash used in operating activities for the nine months ended September 30, 2024 was $10.7M, a significant improvement from $61.2M in the prior year.

Outlook and guidance

• Q4 2024 net revenue guidance is $37M–$43M; full-year 2024 product revenue guidance narrowed to $140M–$146M.

• Adjusted operating expenses for 2024 guided to $101M–$105M; adjusted EBITDA expected between $2M–$5M.

• Management expects current liquidity and working capital facility to be sufficient for at least the next 12 months.

• VAN and NOPAIN Act expected to provide significant tailwinds in 2025.

• Prefilled syringe program progressing, with approval targeted for late 2026 or early 2027.